CANF — Can-Fite BioPharma Ltd.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1536196 ·
Last close
$1.53
Market Cap
$3.28M
52W High
$12.40
52W Low
$1.42
ADV30
58,943
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 8,055,000 | 2,985,000 | 3,200,000 |
| Dec 2025 | — | — | — | — | 9,514,000 | 5,528,000 | 3,922,000 |
| Jun 2025 | — | — | — | — | 7,720,000 | 6,454,000 | 3,536,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-180,790,000
Inventory
—
Receivables
—
ST Investments
$4,058,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$405,000
EBITDA
$-9,730,000
Free Cash Flow
$-5,579,500
Enterprise Value
$-2,001,866
Total Cash
$7,043,000
Total Debt
$49,000
Shares Out
2,142,547
Trailing EPS
$-4.65
Book Value
$2.27
ROE
-211.4%
ROA
-77.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 405,000 | -9,950,000 | -9,828,000 | 9,514,000 | 3,922,000 | 5,592,000 | -8,949,000 |
| Dec 2024 | 674,000 | -8,130,000 | -7,880,000 | 9,120,000 | 3,680,000 | 5,436,000 | -7,637,000 |
| Dec 2023 | 743,000 | -8,195,000 | -7,634,000 | 9,990,000 | 3,746,000 | 6,243,000 | -8,440,000 |
| Dec 2022 | 810,000 | -10,096,000 | -10,173,000 | 9,280,000 | 4,811,000 | 4,472,000 | -10,801,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.27
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CTTH | CTT PHARMACEUTICAL HOLDINGS, INC. | $3.28M | $0.06 | — |
| PMHS | Polomar Health Services, Inc. | $3.55M | $0.13 | — |
| TRAW | Traws Pharma, Inc. | $3.59M | $0.23 | — |
| GRI | GRI Bio, Inc. | $2.95M | $1.35 | — |
| APUS | Apimeds Pharmaceuticals US, Inc. | $2.94M | $1.95 | — |
News headlines (Yahoo Finance, 1h cache)
Can-Fite Pivotal Phase III Psoriasis Study Under an FDA- and EMA-agreed protocol: All Patients Completed Dosing and Interim Analysis Expected Q1 2027
2026-11-18 12:00 · Yahoo
Can-Fite's Piclidenoson Demonstrates Up to 80% Improvement in Kidney Disease Marker in Lowe Syndrome Preclinical Study: Published in Nature Portfolio Journal
2026-11-12 12:00 · Yahoo
Can-Fite Reports Ten-Year Survival Milestone for Advanced Liver Cancer Patient from Phase II Namodenoson Study
2026-11-09 12:00 · Yahoo
Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones
2026-11-06 12:23 · Yahoo
Can-Fite Announces Eurasian Patent Allowance Supporting Piclidenoson Development and Commercialization in Lowe Syndrome
2026-11-02 12:00 · Yahoo
Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026
2026-10-26 11:00 · Yahoo
Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
2026-09-09 11:00 · Yahoo
Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
2026-09-08 12:20 · Yahoo
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
2026-09-02 13:02 · Yahoo
Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
2026-09-02 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.